Announcements Trials
Browse Landscape

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Observational 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3Stomach Neoplasms 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Angiogenesis Inhibitors × Gastrointestinal × Clear all
NCT06777628 2025-01-16

Immunecheck

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Recruiting
100 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06423144 2024-05-21

PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7

Shanghai Zhongshan Hospital

Unknown
150 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04639284 2021-07-26

Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Shanghai Zhongshan Hospital

Unknown
200 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡